Incyte (INCY) News Today $58.98 -0.75 (-1.26%) Closing price 05/9/2025 04:00 PM EasternExtended Trading$58.84 -0.14 (-0.25%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Incyte Q1 Earnings TranscriptMay 12 at 7:16 AM | marketbeat.comAlgert Global LLC Takes Position in Incyte Co. (NASDAQ:INCY)Algert Global LLC purchased a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 46,250 shares of the biopharmaceutical company's stock, valued at approximately $3,194,0May 10 at 4:55 AM | marketbeat.comAxa S.A. Decreases Stake in Incyte Co. (NASDAQ:INCY)Axa S.A. cut its position in Incyte Co. (NASDAQ:INCY - Free Report) by 26.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 83,719 shares of the biopharmaceutical company's stock after selling 29,805 sharMay 9 at 4:41 AM | marketbeat.comIncyte to Present at 2025 BofA Securities Health Care ConferenceMay 8, 2025 | msn.comCubist Systematic Strategies LLC Acquires 192,004 Shares of Incyte Co. (NASDAQ:INCY)Cubist Systematic Strategies LLC lifted its stake in Incyte Co. (NASDAQ:INCY - Free Report) by 270.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 263,019 shares of the biopharmaceutical company's stock after aMay 8, 2025 | marketbeat.comBrevan Howard Capital Management LP Buys 16,164 Shares of Incyte Co. (NASDAQ:INCY)Brevan Howard Capital Management LP increased its stake in Incyte Co. (NASDAQ:INCY - Free Report) by 43.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 52,953 shares of the biopharmaceutical company's stock after purchasing an additional 16,16May 8, 2025 | marketbeat.comIncyte Reports Strong Q1 2025 Financial Results and Pipeline ProgressMay 7, 2025 | msn.comIncyte Co. (NASDAQ:INCY) Shares Acquired by Bellevue Group AGBellevue Group AG increased its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 0.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,157,478 shares of the biopharmaceutical company's stock after purchasingMay 6, 2025 | marketbeat.comFreestone Grove Partners LP Takes Position in Incyte Co. (NASDAQ:INCY)Freestone Grove Partners LP bought a new position in Incyte Co. (NASDAQ:INCY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,462 shares of the biopharmaceutical compaMay 6, 2025 | marketbeat.comNorthern Trust Corp Purchases 150,672 Shares of Incyte Co. (NASDAQ:INCY)Northern Trust Corp boosted its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 9.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,696,123 shares of the biopharmaceutical company's stock after buying an additional 150,672 shares duriMay 6, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Purchases 19,334 Shares of Incyte Co. (NASDAQ:INCY)The Manufacturers Life Insurance Company boosted its position in Incyte Co. (NASDAQ:INCY - Free Report) by 11.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 184,871 shares of the biopharmaceutical company's stock after acquiring an additional 19,3May 6, 2025 | marketbeat.comLabcorp's latest deal targets Incyte Diagnostics, enhancing oncology testing in Pacific NorthwestMay 5, 2025 | bizjournals.comMeiji Yasuda Life Insurance Co Acquires 6,533 Shares of Incyte Co. (NASDAQ:INCY)Meiji Yasuda Life Insurance Co raised its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 90.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,786 shares of the biopharmaceutical company's stock aftMay 5, 2025 | marketbeat.comCaisse DE Depot ET Placement DU Quebec Increases Stock Position in Incyte Co. (NASDAQ:INCY)Caisse DE Depot ET Placement DU Quebec raised its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 8,220.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 416,202 shares of the biopharmaceuticalMay 5, 2025 | marketbeat.comKovitz Investment Group Partners LLC Buys Shares of 4,414 Incyte Co. (NASDAQ:INCY)Kovitz Investment Group Partners LLC purchased a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,414 shares of the biopharmaceutical company's stock, vMay 5, 2025 | marketbeat.comNewEdge Advisors LLC Sells 4,288 Shares of Incyte Co. (NASDAQ:INCY)NewEdge Advisors LLC lessened its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 61.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,684 shares of the biopharmaceuticalMay 5, 2025 | marketbeat.comWilliam Blair Predicts Incyte's Q4 Earnings (NASDAQ:INCY)Incyte Co. (NASDAQ:INCY - Free Report) - William Blair lifted their Q4 2025 earnings estimates for Incyte in a report issued on Tuesday, April 29th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will earn $1.25 per share for the quarter, up from their previous eMay 4, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Decreases Stock Position in Incyte Co. (NASDAQ:INCY)Schonfeld Strategic Advisors LLC cut its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 50.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 165,700 shares of the biopharmaceutical comMay 3, 2025 | marketbeat.comWilliam Blair Issues Optimistic Outlook for Incyte EarningsMay 3, 2025 | americanbankingnews.comKapitalo Investimentos Ltda Acquires New Position in Incyte Co. (NASDAQ:INCY)Kapitalo Investimentos Ltda bought a new position in Incyte Co. (NASDAQ:INCY - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 4,403 shares of the biopharmaceutical company's stock, valued at approximately $304,000. Other large investors also reMay 2, 2025 | marketbeat.comIncyte (NASDAQ:INCY) Announces Earnings Results, Beats Estimates By $0.15 EPSIncyte (NASDAQ:INCY - Get Free Report) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported $1.16 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.15. Incyte had a net margin of 0.77% and a return on equity of 0.05%. The company had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $996.17 million. During the same period last year, the business earned $0.64 EPS. The business's quarterly revenue was up 19.5% on a year-over-year basis.May 1, 2025 | marketbeat.comIncyte Co. (NASDAQ:INCY) Stock Position Increased by AQR Capital Management LLCAQR Capital Management LLC lifted its position in Incyte Co. (NASDAQ:INCY - Free Report) by 29.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,502,813 shares of the biopharmaceutical company's stock after buying an additional 8May 1, 2025 | marketbeat.comVoya Investment Management LLC Raises Stock Position in Incyte Co. (NASDAQ:INCY)Voya Investment Management LLC lifted its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 35.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 169,697 shares of the biopharmaceutical company's stock after acquiring anMay 1, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Acquires 305,264 Shares of Incyte Co. (NASDAQ:INCY)Price T Rowe Associates Inc. MD grew its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 50.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 913,708 shares of the biopharmaceutical company's stock after buying an aMay 1, 2025 | marketbeat.comDimensional Fund Advisors LP Has $91.54 Million Position in Incyte Co. (NASDAQ:INCY)Dimensional Fund Advisors LP cut its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 6.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,325,505 shares of the biopharmaceutical company's stock after selMay 1, 2025 | marketbeat.comIncyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Call TranscriptApril 30, 2025 | msn.comIncyte (INCY) Target Price Raised Following Strong Q1 Performance | INCY Stock NewsApril 30, 2025 | gurufocus.comIncyte (INCY) Target Price Raised Following Strong Q1 Performance | INCY Stock NewsApril 30, 2025 | gurufocus.comIncyte (INCY) Receives Adjusted Price Target from TD Cowen | INCY Stock NewsApril 30, 2025 | gurufocus.comBofA Boosts Incyte (INCY) Price Target Following Q1 Results | INCY Stock NewsApril 30, 2025 | gurufocus.comIncyte’s Growth Prospects Hindered by Jakafi’s Exclusivity Loss and Strategic LimitationsApril 30, 2025 | tipranks.comIncyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ...April 30, 2025 | gurufocus.comIncyte Corporation 2025 Q1 - Results - Earnings Call PresentationApril 29, 2025 | seekingalpha.comIncyte’s Promising Growth Potential and Strategic Positioning Amidst Market ChallengesApril 29, 2025 | tipranks.comIncyte (NASDAQ:INCY) Delivers Strong Q1 NumbersApril 29, 2025 | uk.finance.yahoo.comIncyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecastApril 29, 2025 | msn.comIncyte raises 2025 Jakafi revenue guidance to $3B amid strong Q1 growthApril 29, 2025 | msn.comIncyte Corporation (INCY) Q1 2025 Earnings Call TranscriptApril 29, 2025 | seekingalpha.comIncyte raises 2025 sales forecast for blood cancer drug after solid quarterApril 29, 2025 | reuters.comIncyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsApril 29, 2025 | businesswire.comSusquehanna Fundamental Investments LLC Buys Shares of 210,237 Incyte Co. (NASDAQ:INCY)Susquehanna Fundamental Investments LLC purchased a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 210,237 shares of the biopharmaceuticalApril 29, 2025 | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Acquired by Banco Bilbao Vizcaya Argentaria S.A.Banco Bilbao Vizcaya Argentaria S.A. increased its stake in Incyte Co. (NASDAQ:INCY - Free Report) by 409.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,023 shares of the biophaApril 29, 2025 | marketbeat.comXTX Topco Ltd Reduces Stock Position in Incyte Co. (NASDAQ:INCY)XTX Topco Ltd decreased its holdings in Incyte Co. (NASDAQ:INCY - Free Report) by 84.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,491 shares of the biopharmaceutical company's stock after sellingApril 29, 2025 | marketbeat.comRaymond James Financial Inc. Makes New $3.62 Million Investment in Incyte Co. (NASDAQ:INCY)Raymond James Financial Inc. purchased a new stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 52,449 shares of the biopharmaceutical company's stock, valued at aApril 29, 2025 | marketbeat.comIncyte (INCY) Set to Announce Q1 Earnings, Analysts CautiousApril 28, 2025 | gurufocus.comState of Tennessee Department of Treasury Has $4.23 Million Holdings in Incyte Co. (NASDAQ:INCY)State of Tennessee Department of Treasury grew its position in Incyte Co. (NASDAQ:INCY - Free Report) by 47.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 61,199 shares of the biopharmaceutical company's stock after purchasing an adApril 28, 2025 | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Purchased by Tower Research Capital LLC TRCTower Research Capital LLC TRC raised its stake in Incyte Co. (NASDAQ:INCY - Free Report) by 247.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 14,150 shares of the biopharmaceutical company's stock after purchasing an addiApril 28, 2025 | marketbeat.comIncyte (INCY) Q1 Earnings Report Preview: What To Look ForApril 28, 2025 | finance.yahoo.comHsbc Holdings PLC Lowers Holdings in Incyte Co. (NASDAQ:INCY)Hsbc Holdings PLC reduced its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 16.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,042,059 shares of the biopharmaceuticApril 27, 2025 | marketbeat.comIncyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research ...April 25, 2025 | gurufocus.com Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address INCY Media Mentions By Week INCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INCY News Sentiment▼1.280.86▲Average Medical News Sentiment INCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INCY Articles This Week▼1515▲INCY Articles Average Week Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today BioMarin Pharmaceutical News Today Exelixis News Today Neurocrine Biosciences News Today Exact Sciences News Today Repligen News Today Halozyme Therapeutics News Today Madrigal Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INCY) was last updated on 5/12/2025 by MarketBeat.com Staff From Our PartnersThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was d...Investors Alley | SponsoredConfidential Economic AdvisoryI've hesitated for months to record this video. The very act of sharing these details makes me deeply uncom...InvestorPlace | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
